Halozyme Therapeutics (HALO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Halozyme Therapeutics (HALO) is Moderate Outperform.

The composite score behind that read is +0.21, weighing +0.15 of bullish evidence against -0.18 bearish.

Halozyme Therapeutics last closed at $110.42, +0.53% on the session.

Against the IVW growth benchmark the position is -0.27% over the forecast window.

The read is built from 15 underlying insights — 10 bullish and 5 bearish.

Agreement across those insights is 67%.

Halozyme Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Halozyme Therapeutics in the 25th percentile on valuation and the 97th percentile on return on equity, where 100 is best.

Halozyme Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $12.47B.

StockMap tracks Halozyme Therapeutics as the 23rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Halozyme Therapeutics ranks 9th of 381 in the group, against a group median of -0.08.